It was worth mentioning that this comparison focusing on the EGFR‐mutant NSCLC subgroup and the former achieving better OS via pembrolizumab targeting PD‐1 pathway instead of EGFR directly. Here, EGFR is linked to non-small cell lung carcinoma.